|
|
|
| Latest News |
| April 16, 2014 |
Presenters Announced for The Family and Researcher Poster Session at The Annual Spinal Muscular Atrophy Conference. | Over thirty posters will be presented during the session. |
|
|
|
| April 15, 2014 |
Update on Families of Spinal Muscular Atrophy Funding to The California Institute of Biomedical Research | Developing new therapies for SMA is the driving force behind Families of SMA funding strategy. To achieve this goal, Families of SMA funds successful and innovative scientists like Dr. Peter Schultz. |
|
|
|
| April 10, 2014 |
Families of Spinal Muscular Atrophy Thanks our Sponsors for The 2014 Annual SMA Conference. | Families of SMA is pleased to announce that we currently have 18 sponsors registered for the upcoming 2014 Annual SMA Conference. |
|
|
|
| April 9, 2014 |
Families of Spinal Muscular Atrophy Awards New Research Funding of $50,000 to Dr. Lyndsay Murray. | Lyndsay Murray of The University of Edinburgh will explore the reasons causing motor neuron cell death in SMA. |
|
|
|
| April 8, 2014 |
Families of Spinal Muscular Atrophy Announces Panelists for The Research Question and Answer Session at The 2014 Annual SMA Conference. | Leading experts will address new advances, strategies, and challenges in SMA drug development. |
|
|
|
| April 7, 2014 |
Families of SMA Spring Fundraising Event Season is Finally Here to Help Fund a Cure for Spinal Muscular Atrophy. | Thanks to so many amazing Chapter leaders and SMA Families, we are aiming to raise over $2.1 Million to fund advancements in SMA research and critical family support and patient care programs. |
|
|
|
| April 2, 2014 |
Families of Spinal Muscular Atrophy is Thrilled to Announce that Registration for The 2014 Annual SMA Conference Has Now Exceeded 1,000 | With just 5 weeks remaining until registration closes on May 8th, the 2014 Annual SMA Conference, held on June 12th – June 15th, will be a conference not to miss! |
|
|
|
| April 1, 2014 |
Regenx Biosciences and Avexis Enter into Agreement for The Development of Treatments for Spinal Muscular Atrophy Using NavRaav9 Vectors | The license is important for the successful development and commercialization of AAV9 based gene therapy for SMA. |
|
|
|
|
|
|
|
|
|
|
